Somewhat, going by the main randomized trial so far. In 48 adults with alcohol use disorder, nine weeks of low-dose semaglutide (the drug in Ozempic) cut the alcohol they drank in a lab session, their drinks per drinking day and their craving versus placebo, but not their number of drinking days. Using it for drinking is off-label.
One of the more surprising things people report on Ozempic, Wegovy and Zepbound is that they simply stop wanting to drink as much. For years that was anecdote. Now there’s a randomized trial — and it’s genuinely interesting, but it says something more specific than “GLP-1 cures drinking.” Here’s what it actually found.
Why the effect is plausible
GLP-1 receptors aren’t only in the gut and pancreas — they’re also in brain regions that govern reward and motivation. The leading idea is that GLP-1 drugs dampen the reward signal from consuming things, which is why so many users describe both food and alcohol becoming less compelling. That shared mechanism is what makes the “quiets the craving” reports worth taking seriously rather than dismissing.
What the trial actually showed
The key evidence is a randomized, placebo-controlled trial of once-weekly semaglutide in adults with alcohol use disorder (n = 48, nine weeks, doses stepped from 0.25 mg up to 1 mg a week).[1] Its primary test was a supervised lab drinking session: after treatment, the semaglutide group drank less alcohol than the placebo group (β −0.48, 95% CI −0.85 to −0.11) and reached a lower peak breath-alcohol level, which the authors describe as medium-to-large effects. In daily life, semaglutide reduced how much people drank on the days they drank (β −0.41, 95% CI −0.73 to −0.09) and weekly craving (β −0.39), and it predicted bigger drops in heavy drinking over time, compared with placebo. That’s a real, prospectively tested signal in exactly the population where it matters.
| Outcome | Semaglutide vs placebo |
|---|---|
| Drinks per drinking day | Reduced — a clear effect |
| Heavy-drinking days | Reduced |
| Alcohol craving | Reduced |
| Alcohol drunk in a lab session (primary outcome) | Reduced (medium-to-large effect) |
| Number of drinking days | Not significantly reduced |
| Average drinks per calendar day | Not significantly reduced |
| Approved for alcohol use disorder? | No — this is off-label, early-stage research |
The safety angle worth knowing
Separately from the craving question, mixing alcohol with a GLP-1 has practical considerations. These drugs slow stomach emptying and commonly cause nausea, and alcohol is itself a GI irritant, so drinking can amplify nausea and stomach upset — and alcohol’s own calories and effect on blood sugar work against the metabolic goals most people are taking the drug for. None of that is unique to GLP-1 drugs, but the slowed-gut interaction makes “a heavy night” feel worse for many users.
The honest bottom line
The “Ozempic made me lose interest in drinking” reports now have real trial support — but the support is specific: in people with alcohol use disorder, semaglutide reduced how heavily they drank and their craving, more than it changed whether they drank at all.[1]It’s a genuinely promising, mechanism-consistent finding — and also an off-label, early-stage one, not an approved treatment. If quieting cravings is what draws you to these drugs, see how the same reward-dampening shows up across the class in our semaglutide evidence guide and the broader side-effects timeline.